Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-030414
Filing Date
2025-03-03
Accepted
2025-03-03 08:45:26
Documents
86
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K pmvp-20241231.htm   iXBRL 10-K 3294061
2 EX-19.1 pmvp-ex19_1.htm EX-19.1 121655
3 EX-23.1 pmvp-ex23_1.htm EX-23.1 8861
4 EX-31.1 pmvp-ex31_1.htm EX-31.1 20030
5 EX-31.2 pmvp-ex31_2.htm EX-31.2 19819
6 EX-32.1 pmvp-ex32_1.htm EX-32.1 11996
7 EX-32.2 pmvp-ex32_2.htm EX-32.2 12264
8 GRAPHIC img250979541_0.jpg GRAPHIC 82115
9 GRAPHIC img250979541_1.jpg GRAPHIC 82115
10 GRAPHIC img250979541_2.jpg GRAPHIC 837731
  Complete submission text file 0000950170-25-030414.txt   14347350

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pmvp-20241231.xsd EX-101.SCH 1491038
89 EXTRACTED XBRL INSTANCE DOCUMENT pmvp-20241231_htm.xml XML 2125169
Mailing Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540
Business Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540 (609) 642-6670
PMV Pharmaceuticals, Inc. (Filer) CIK: 0001699382 (see all company filings)

EIN.: 463218129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39539 | Film No.: 25694122
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)